{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:41:45Z","timestamp":1792748505590,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1937971"],"award-info":[{"award-number":["1937971"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-026-01818-0","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:01:29Z","timestamp":1792746089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gradient-driven microfluidic framework for the screening of ratiometric drug combinations towards precision oncology in paediatric leukaemia"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-2237","authenticated-orcid":false,"given":"E. Kendall","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1412-6963","authenticated-orcid":false,"given":"Theodora T.","family":"Alese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3621-8664","authenticated-orcid":false,"given":"Ryan J.","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie O.","family":"Musick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita I.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-8802","authenticated-orcid":false,"given":"Melissa L.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8774-0180","authenticated-orcid":false,"given":"Christopher C.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0325-7990","authenticated-orcid":false,"given":"Wilbur A.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"1818_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41571-018-0136-6","volume":"16","author":"C-H Pui","year":"2019","unstructured":"Pui, C.-H., Nichols, K. E. & Yang, J. J. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat. Rev. Clin. Oncol. 16, 227\u2013240 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1818_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30585","volume":"70","author":"EA Raetz","year":"2023","unstructured":"Raetz, E. A. et al. Children\u2019s Oncology Group blueprint for research: acute lymphoblastic leukemia. Pediatr. Blood Cancer 70, e30585 (2023).","journal-title":"Pediatr. Blood Cancer"},{"key":"1818_CR3","doi-asserted-by":"publisher","first-page":"hvaf086.755","DOI":"10.1093\/clinchem\/hvaf086.755","volume":"71","author":"E Williams","year":"2025","unstructured":"Williams, E. et al. B-370 high efficiency gradient-based combinatorial drug profiling in a microfluidic device predicts personalized outcomes in pediatric leukemia. Clin. Chem 71, hvaf086.755 (2025).","journal-title":"Clin. Chem"},{"key":"1818_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pcl.2014.09.006","volume":"62","author":"SL Cooper","year":"2015","unstructured":"Cooper, S. L. & Brown, P. A. Treatment of pediatric acute lymphoblastic leukemia. Pediatr. Clin. North Am. 62, 61\u201373 (2015).","journal-title":"Pediatr. Clin. North Am."},{"key":"1818_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood.2019001557","volume":"135","author":"DT Teachey","year":"2020","unstructured":"Teachey, D. T. & O\u2019Connor, D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood 135, 159\u2013166 (2020).","journal-title":"Blood"},{"key":"1818_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semcancer.2020.10.013","volume":"84","author":"TH Tran","year":"2022","unstructured":"Tran, T. H. & Hunger, S. P. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities. Semin. Cancer Biol. 84, 144\u2013152 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"1818_CR7","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.3390\/cancers13164068","volume":"13","author":"SHR Lee","year":"2021","unstructured":"Lee, S. H. R., Li, Z., Tai, S. T., Oh, B. L. Z. & Yeoh, A. E. J. Genetic alterations in childhood acute lymphoblastic leukemia: interactions with clinical features and treatment response. Cancers 13, 4068 (2021).","journal-title":"Cancers"},{"key":"1818_CR8","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba, H. & Mullighan, C. G. Pediatric acute lymphoblastic leukemia. Haematologica 105, 2524\u20132539 (2020).","journal-title":"Haematologica"},{"key":"1818_CR9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"CL Tourneau","year":"2015","unstructured":"Tourneau, C. L. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324\u20131334 (2015).","journal-title":"Lancet Oncol."},{"key":"1818_CR10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","volume":"29","author":"PJ O\u2019Dwyer","year":"2023","unstructured":"O\u2019Dwyer, P. J. et al. The NCI-MATCH trial: lessons for precision oncology. Nat. Med. 29, 1349\u20131357 (2023).","journal-title":"Nat. Med."},{"key":"1818_CR11","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas, V. et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129, e26\u2013e37 (2017).","journal-title":"Blood"},{"key":"1818_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41591-022-02112-7","volume":"29","author":"SHR Lee","year":"2023","unstructured":"Lee, S. H. R. et al. Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response. Nat. Med. 29, 170\u2013179 (2023).","journal-title":"Nat. Med."},{"key":"1818_CR13","doi-asserted-by":"publisher","first-page":"E7554","DOI":"10.1073\/pnas.1703094114","volume":"114","author":"SE Kurtz","year":"2017","unstructured":"Kurtz, S. E. et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc. Natl Acad. Sci. 114, E7554\u2013E7563 (2017).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1818_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth, C. et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 12, 372\u2013387 (2022).","journal-title":"Cancer Discov."},{"key":"1818_CR15","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1039\/C5LC00923E","volume":"15","author":"S Sarkar","year":"2015","unstructured":"Sarkar, S., Cohen, N., Sabhachandani, P. & Konry, T. Phenotypic drug profiling in droplet microfluidics for better targeting of drug-resistant tumors. Lab Chip 15, 4441\u20134450 (2015).","journal-title":"Lab Chip"},{"key":"1818_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33055-0","volume":"8","author":"T Mulholland","year":"2018","unstructured":"Mulholland, T. et al. Drug screening of biopsy-derived spheroids using a self-generated microfluidic concentration gradient. Sci. Rep. 8, 14672 (2018).","journal-title":"Sci. Rep."},{"key":"1818_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1073\/pnas.1113324109","volume":"109","author":"OJ Miller","year":"2012","unstructured":"Miller, O. J. et al. High-resolution dose\u2013response screening using droplet-based microfluidics. Proc. Natl Acad. Sci. 109, 378\u2013383 (2012).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1818_CR18","doi-asserted-by":"publisher","unstructured":"Microfluidic arrays of breast tumor spheroids for drug screening and personalized cancer therapies. Adv. Healthc. Mater. 11, 2101085 https:\/\/doi.org\/10.1002\/adhm.202101085 (2022).","DOI":"10.1002\/adhm.202101085"},{"key":"1818_CR19","first-page":"1","volume":"4","author":"LF Horowitz","year":"2020","unstructured":"Horowitz, L. F. et al. Multiplexed drug testing of tumor slices using a microfluidic platform. Npj Precis. Oncol. 4, 1\u201315 (2020).","journal-title":"Npj Precis. Oncol."},{"key":"1818_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04919-w","volume":"9","author":"F Eduati","year":"2018","unstructured":"Eduati, F. et al. A microfluidics platform for combinatorial drug screening on cancer biopsies. Nat. Commun. 9, 2434 (2018).","journal-title":"Nat. Commun."},{"key":"1818_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32197-0","volume":"13","author":"L Mathur","year":"2022","unstructured":"Mathur, L. et al. Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets. Nat. Commun. 13, 4450 (2022).","journal-title":"Nat. Commun."},{"key":"1818_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19058-4","volume":"11","author":"B Schuster","year":"2020","unstructured":"Schuster, B. et al. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat. Commun. 11, 5271 (2020).","journal-title":"Nat. Commun."},{"key":"1818_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01593-2","volume":"8","author":"AE Cetin","year":"2017","unstructured":"Cetin, A. E. et al. Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. Nat. Commun. 8, 1613 (2017).","journal-title":"Nat. Commun."},{"key":"1818_CR24","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1039\/D1LC00525A","volume":"21","author":"L Li","year":"2021","unstructured":"Li, L. et al. A high-throughput, open-space and reusable microfluidic chip for combinational drug screening on tumor spheroids. Lab Chip 21, 3924\u20133932 (2021).","journal-title":"Lab Chip"},{"key":"1818_CR25","doi-asserted-by":"publisher","first-page":"106651","DOI":"10.1016\/j.isci.2023.106651","volume":"26","author":"R Fevre","year":"2023","unstructured":"Fevre, R. et al. Combinatorial drug screening on 3D Ewing sarcoma spheroids using droplet-based microfluidics. iScience 26, 106651 (2023).","journal-title":"iScience"},{"key":"1818_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41378-020-00200-7","volume":"6","author":"E Sweet","year":"2020","unstructured":"Sweet, E. et al. 3D microfluidic gradient generator for combination antimicrobial susceptibility testing. Microsyst. Nanoeng. 6, 1\u201314 (2020).","journal-title":"Microsyst. Nanoeng."},{"key":"1818_CR27","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jconrel.2023.07.045","volume":"361","author":"JM Kelvin","year":"2023","unstructured":"Kelvin, J. M. et al. Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia. J. Controlled Release 361, 470\u2013482 (2023).","journal-title":"J. Controlled Release"},{"key":"1818_CR28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/10428194.2019.1660970","volume":"61","author":"M Alfayez","year":"2020","unstructured":"Alfayez, M., Kantarjian, H., Kadia, T., Ravandi-Kashani, F. & Daver, N. CPX-351 (vyxeos) in AML. Leuk. Lymphoma 61, 288\u2013297 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"1818_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","volume":"33","author":"P Tardi","year":"2009","unstructured":"Tardi, P. et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk. Res. 33, 129\u2013139 (2009).","journal-title":"Leuk. Res."},{"key":"1818_CR30","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1021\/acs.molpharmaceut.8b00246","volume":"15","author":"YT Shen","year":"2018","unstructured":"Shen, Y. T., Evans, J. C., Zafarana, G., Allen, C. & Piquette-Miller, M. BRCA status does not predict synergism of a carboplatin and olaparib combination in high-grade serous ovarian cancer cell lines. Mol. Pharm. 15, 2742\u20132753 (2018).","journal-title":"Mol. Pharm."},{"key":"1818_CR31","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/acs.molpharmaceut.7b00843","volume":"15","author":"S Eetezadi","year":"2018","unstructured":"Eetezadi, S. et al. Ratio-dependent synergism of a doxorubicin and olaparib combination in 2D and spheroid models of ovarian cancer. Mol. Pharm. 15, 472\u2013485 (2018).","journal-title":"Mol. Pharm."},{"key":"1818_CR32","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/1947601912440575","volume":"2","author":"RJ Tallarida","year":"2011","unstructured":"Tallarida, R. J. Quantitative methods for assessing drug synergism. Genes Cancer 2, 1003\u20131008 (2011).","journal-title":"Genes Cancer"},{"key":"1818_CR33","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","volume":"5","author":"LD Mayer","year":"2006","unstructured":"Mayer, L. D. et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5, 1854\u20131863 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"1818_CR34","doi-asserted-by":"publisher","first-page":"7848","DOI":"10.1182\/blood-2022-162384","volume":"140","author":"EK Williams","year":"2022","unstructured":"Williams, E. K. et al. High-efficiency multi-drug functional profiling in a microfluidic device towards personalized predictions in pediatric leukemia. Blood 140, 7848\u20137849 (2022).","journal-title":"Blood"},{"key":"1818_CR35","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2021-152079","volume":"138","author":"EK Williams","year":"2021","unstructured":"Williams, E. K. et al. Microfluidic multi-drug and multi-dose functional profiling towards personalized clinical predictions in pediatric leukemia. Blood 138, 2960 (2021).","journal-title":"Blood"},{"key":"1818_CR36","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/smll.201501905","volume":"12","author":"SGM Uzel","year":"2016","unstructured":"Uzel, S. G. M. et al. Simultaneous or sequential orthogonal gradient formation in a 3D cell culture microfluidic platform. Small Weinh. Bergstr. Ger. 12, 612\u2013622 (2016).","journal-title":"Small Weinh. Bergstr. Ger."},{"key":"1818_CR37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41592-019-0455-2","volume":"16","author":"A Manfrin","year":"2019","unstructured":"Manfrin, A. et al. Engineered signaling centers for the spatially controlled patterning of human pluripotent stem cells. Nat. Methods 16, 640\u2013648 (2019).","journal-title":"Nat. Methods"},{"key":"1818_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","volume":"8","author":"CT Meyer","year":"2019","unstructured":"Meyer, C. T. et al. Quantifying drug combination synergy along potency and efficacy axes. Cell Syst. 8, 97\u2013108.e16 (2019).","journal-title":"Cell Syst."},{"key":"1818_CR39","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.tips.2019.08.008","volume":"40","author":"P Sen","year":"2019","unstructured":"Sen, P., Saha, A. & Dixit, N. M. You cannot have your synergy and efficacy too. Trends Pharmacol. Sci. 40, 811\u2013817 (2019).","journal-title":"Trends Pharmacol. Sci."},{"key":"1818_CR40","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.cels.2021.08.004","volume":"12","author":"J Larkins-Ford","year":"2021","unstructured":"Larkins-Ford, J. et al. Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis. Cell Syst. 12, 1046\u20131063.e7 (2021).","journal-title":"Cell Syst."},{"key":"1818_CR41","doi-asserted-by":"publisher","first-page":"e50036","DOI":"10.7554\/eLife.50036","volume":"8","author":"AC Palmer","year":"2019","unstructured":"Palmer, A. C., Chidley, C. & Sorger, P. K. A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. eLife 8, e50036 (2019).","journal-title":"eLife"},{"key":"1818_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.chemolab.2004.12.011","volume":"78","author":"I-G Chong","year":"2005","unstructured":"Chong, I.-G. & Jun, C.-H. Performance of some variable selection methods when multicollinearity is present. Chemom. Intell. Lab. Syst. 78, 103\u2013112 (2005).","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"1818_CR43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fonc.2014.00108","volume":"4","author":"SK Tasian","year":"2014","unstructured":"Tasian, S. K., Teachey, D. T. & Rheingold, S. R. Targeting the PI3K\/mTOR pathway in pediatric hematologic malignancies. Front. Oncol. 4, 108 (2014).","journal-title":"Front. Oncol."},{"key":"1818_CR44","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3390\/ijms19071878","volume":"19","author":"C Evangelisti","year":"2018","unstructured":"Evangelisti, C., Chiarini, F., McCubrey, J. A. & Martelli, A. M. Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: an update. Int. J. Mol. Sci. 19, 1878 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1818_CR45","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer, A. C. & Sorger, P. K. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 171, 1678\u20131691.e13 (2017).","journal-title":"Cell"},{"key":"1818_CR46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","volume":"603","author":"P Jaaks","year":"2022","unstructured":"Jaaks, P. et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature 603, 166\u2013173 (2022).","journal-title":"Nature"},{"key":"1818_CR47","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/blood.V90.7.2723","volume":"90","author":"GJL Kaspers","year":"1997","unstructured":"Kaspers, G. J. L. et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90, 2723\u20132729 (1997).","journal-title":"Blood"},{"key":"1818_CR48","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2003.11.031","volume":"21","author":"ML Den Boer","year":"2003","unstructured":"Den Boer, M. L. et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J. Clin. Oncol. 21, 3262\u20133268 (2003).","journal-title":"J. Clin. Oncol."},{"key":"1818_CR49","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1535-7163.MCT-23-0642","volume":"23","author":"SC Patterson","year":"2024","unstructured":"Patterson, S. C., Pomeroy, A. E. & Palmer, A. C. Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Mol. Cancer Ther. 23, 995\u20131009 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"1818_CR50","doi-asserted-by":"publisher","first-page":"11115","DOI":"10.1073\/pnas.1103581108","volume":"108","author":"WJ Polacheck","year":"2011","unstructured":"Polacheck, W. J., Charest, J. L. & Kamm, R. D. Interstitial flow influences direction of tumor cell migration through competing mechanisms. Proc. Natl Acad. Sci.108, 11115\u201311120 (2011).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1818_CR51","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/01.ATV.20.10.2220","volume":"20","author":"S Wang","year":"2000","unstructured":"Wang, S. & Tarbell, J. M. Effect of fluid flow on smooth muscle cells in a 3-dimensional collagen gel model. Arterioscler. Thromb. Vasc. Biol. 20, 2220\u20132225 (2000).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1818_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44764-5","volume":"9","author":"T Fischer","year":"2019","unstructured":"Fischer, T., Hayn, A. & Mierke, C. T. Fast and reliable advanced two-step pore-size analysis of biomimetic 3D extracellular matrix scaffolds. Sci. Rep. 9, 8352 (2019).","journal-title":"Sci. Rep."},{"key":"1818_CR53","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/S0006-3495(02)73933-7","volume":"83","author":"S Ramanujan","year":"2002","unstructured":"Ramanujan, S. et al. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys. J. 83, 1650\u20131660 (2002).","journal-title":"Biophys. J."},{"key":"1818_CR54","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1634\/stemcells.22-6-1111","volume":"22","author":"J Cooperman","year":"2004","unstructured":"Cooperman, J., Neely, R., Teachey, D. T., Grupp, S. & Choi, J. K. Cell division rates of primary human precursor B cells in culture reflect in vivo rates. Stem Cells 22, 1111\u20131120 (2004).","journal-title":"Stem Cells"},{"key":"1818_CR55","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/leu.2012.337","volume":"27","author":"AJ Yost","year":"2013","unstructured":"Yost, A. J. et al. Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts. Leukemia 27, 1437\u20131440 (2013).","journal-title":"Leukemia"},{"key":"1818_CR56","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1182\/blood-2008-02-138172","volume":"113","author":"F Armstrong","year":"2009","unstructured":"Armstrong, F. et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 113, 1730\u20131740 (2009).","journal-title":"Blood"},{"key":"1818_CR57","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1038\/leu.2017.136","volume":"31","author":"C Delgado-Martin","year":"2017","unstructured":"Delgado-Martin, C. et al. JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia 31, 2568\u20132576 (2017).","journal-title":"Leukemia"},{"key":"1818_CR58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/blood.V92.1.259.413k21_259_266","volume":"92","author":"GJL Kaspers","year":"1998","unstructured":"Kaspers, G. J. L. et al. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 92, 259\u2013266 (1998).","journal-title":"Blood"},{"key":"1818_CR59","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1182\/blood.V89.8.2959","volume":"89","author":"T Hongo","year":"1997","unstructured":"Hongo, T., Yajima, S., Sakurai, M., Horikoshi, Y. & Hanada, R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 89, 2959\u20132965 (1997).","journal-title":"Blood"},{"key":"1818_CR60","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"1818_CR61","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston, D. R. & Davis, M. Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin. Cancer Res. 23, 3489\u20133498 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1818_CR62","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","volume":"11","author":"H Inaba","year":"2010","unstructured":"Inaba, H. & Pui, C.-H. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 11, 1096\u20131106 (2010).","journal-title":"Lancet Oncol."},{"key":"1818_CR63","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btaa826","volume":"37","author":"DJ Wooten","year":"2021","unstructured":"Wooten, D. J. & Albert, R. Synergy: a Python library for calculating, analyzing and visualizing drug combination synergy. Bioinformatics 37, 1473\u20131474 (2021).","journal-title":"Bioinformatics"},{"key":"1818_CR64","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng, S. et al. SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinform. 20, 587\u2013596 (2022).","journal-title":"Genomics Proteomics Bioinform."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01818-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01818-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01818-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:01:31Z","timestamp":1792746091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01818-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":64,"alternative-id":["1818"],"URL":"https:\/\/doi.org\/10.1038\/s41551-026-01818-0","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"18 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}